Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Kozak

Cardiovascular Disease Winston Salem, NC Medical Doctor

NPI 1073900551 CMS profile 5669014

Medical Center Blvd, Winston Salem, NC 27157

Open in the dashboard

General payments

$44,398

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Kozak of Winston Salem, NC is reported in the CMS Open Payments database as having received $44,398 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,061 16
2024 General $2,649 25
2023 General $3,407 22
2022 General $2,227 27
2021 General $34,204 14
2020 General $529 9
2019 General $319 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Kozak
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Patrick Kozak were reported at $1,061. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Patrick Kozak Cardiovascular Disease median Middle half National median
2019 $319 $450 $127–$1,392 $163
2020 $529 $242 $77–$751 $114
2021 $34,204 $335 $101–$1,037 $132
2022 $2,227 $395 $121–$1,211 $149
2023 $3,407 $443 $136–$1,283 $160
2024 $2,649 $450 $136–$1,323 $164
2025 $1,061 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $22,531 29 payments
  2. Abbott Laboratories $18,721 52 payments
  3. Boston Scientific Corporation $1,709 11 payments
  4. Biosense Webster, Inc. $363 9 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $341 5 payments
  6. Biotronik Inc. $211 3 payments
  7. Atricure, Inc. $208 3 payments
  8. AstraZeneca Pharmaceuticals LP $183 2 payments
  9. Abiomed $103 1 payment
  10. Janssen Pharmaceuticals, Inc $15 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $35,000 4 payments
  2. Travel and Lodging $4,617 25 payments
  3. Food and Beverage $3,145 76 payments
  4. Education $1,636 12 payments
Products named General payments · program years 2019–2025
  1. AVEIR Cardiac Rhythm Management $1,349 9 payments
  2. ENSITE PRECISION $1,307 17 payments
  3. AVEIR Cardiac Rhythm Management $899 7 payments
  4. QUADRA ASSURA $490 2 payments
  5. LifeVest $341 5 payments
  6. AVEIR Structural Heart $293 1 payment
  7. AVEIR Structural Heart $258 2 payments
  8. AFFERA MAPPING SYSTEM $233 6 payments
  9. Adapta $216 1 payment
  10. Ensite Cardiac Mapping System $209 1 payment
  11. Other $2,538 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

580

Median for Cardiology: 2,533

Drug cost

$195,762

Median for Cardiology: $485,213

Branded share of claims

42.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 152 $135,771
Xarelto Rivaroxaban Brand 37 $37,031
Entresto Sacubitril/Valsartan Brand 16 $13,449
Dofetilide Generic 39 $3,982
Flecainide Acetate Generic 61 $2,204
Mexiletine Hcl Generic 19 $969
Metoprolol Succinate Generic 89 $757
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 23 $480
Sotalol Sotalol Hcl Brand 20 $399
Amiodarone Hcl Generic 34 $186

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$84,101

Medicare's payments for the services billed

Medicare patients

579

Average age 75

Services billed

1,153

273 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 62%
Arthritis 53%
Heart failure 52%
Ischemic heart disease 50%
Chronic kidney disease 44%
Diabetes 41%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record